Spots Global Cancer Trial Database for Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients

Official Title: Single-dose Preoperative Partial Breast Irradiation in Low-risk Breast Cancer Patients

Study ID: NCT05350722

Conditions

Breast Cancer

Interventions

Single dose ablative radiotherapy

Study Description

Brief Summary: In this ABLATIVE-2 trial, low-risk breast cancer patients will be treated with MRI-guided single dose preoperative partial breast radiotherapy to assess the rate of pathologic complete response after an interval of six to twelve months between radiotherapy and surgery. Response monitoring will be assessed using MRI and markers in blood and tumor tissue to enable prediction of pathologic response.

Detailed Description: Patients will receive single-dose preoperative radiotherapy followed by breast conserving surgery (BCS) at 12 months after radiotherapy, as long as follow-up MRI scans show a complete radiologic response. In case of incomplete radiologic response, BCS will be performed at 6 months after radiotherapy. BCS is performed earlier when progressive disease is found on MRI. In the follow-up period between radiotherapy and surgery, tumor response will be monitored using MRI every 3 months. After surgery, patients will be followed up until 10 years after radiotherapy treatment to assess oncological outcomes, toxicity, cosmetic outcome and quality of life.